Ibrutinib-induced rapid response in chemotherapy-refractory Richter's Syndrome

被引：0
|
作者：
Fischer-Maranta, A. [1 ]
Bastian, S. [1 ]
Mey, U. [1 ]
Cogliatti, S. [2 ]
Hohloch, K. [1 ,3 ]
机构：
[1] Kantonspital Graubunden, Hamatol & Onkol, Chur, Switzerland
[2] Kantonspital St Gallen, Inst Pathol, St Gallen, Switzerland
[3] Uniklin Goettingen, Hamatol Onkol, Gottingen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P534
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [31] Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion
    Bielack, S. S.
    Cox, M. C.
    Nathrath, M.
    Apel, K.
    Blattmann, C.
    Holl, T.
    Jenewein, R.
    Klenk, U.
    Klothaki, P.
    Mueller-Abt, P.
    Ortega-Lawerenz, S.
    Reynolds, M.
    Scheer, M.
    Simon-Klingenstein, K.
    Stegmaier, S.
    Tupper, R.
    Vokuhl, C.
    von Kalle, T.
    ANNALS OF ONCOLOGY, 2019, 30 : VIII31 - VIII35
  • [32] Rapid Response to Mirtazapine in Cyclic Vomiting Syndrome Refractory to Conventional Prokinetics
    Bae, Seung Min
    Kang, Seung-Gul
    Lee, Yu Jin
    Cho, Seong-Jin
    Seo, Chang Min
    PSYCHOSOMATICS, 2014, 55 (03) : 311 - 312
  • [33] Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma
    Venkatesh, H
    Di Bella, N
    Flynn, TP
    Vellek, MJ
    Boehm, KA
    Asmar, L
    CLINICAL LYMPHOMA, 2004, 5 (02): : 110 - 115
  • [34] Outcome in patients with Richter's syndrome treated with chemotherapy and/or immunotherapy with or without stem cell transplantation
    Tsimberidou, A
    O'Brien, S
    Khouri, I
    Giles, F
    Kantarjian, H
    Smith, S
    Lerner, S
    Keating, M
    ANNALS OF ONCOLOGY, 2005, 16 : 44 - 44
  • [35] A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax (GIVeRS) in Patients with Richter's Syndrome
    Tadmor, Tamar
    Benjamini, Ohad
    Goldschmidt, Neta
    Kreiniz, Natalia
    Bairey, Osnat
    Harel, Reut
    Inbar, Tsofia
    Wolach, Ofir
    Herishanu, Yair
    BLOOD, 2023, 142
  • [36] Rapid progression to Richter's syndrome in patient with chronic lymphocytic leukemia and near triploid karyotype
    Fekete, Marija Dencic
    Terzic, Tatjana
    Jakovic, Ljubomir
    Djurasinovic, Vladislava
    Djurasevic, Teodora Karan
    Radojkovic, Milica
    Pavlovic, Sonja
    Bogdanovic, Andrija
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 529 - 530
  • [37] Sustained antitumor response to lenvatinib with weekend-off and alternate-day administration in chemotherapy-refractory thymic carcinoma: a case report
    Sunaga, Noriaki
    Miura, Yosuke
    Sakurai, Reiko
    Ohshima, Sohei
    Uno, Shogo
    Muto, Sohei
    Sato, Mari
    Tsurumaki, Hiroaki
    Yatomi, Masakiyo
    Koga, Yasuhiko
    Ohtaki, Yoichi
    Nagashima, Toshiteru
    Okano, Naoko
    Kubo, Nobuteru
    Maeno, Toshitaka
    Hisada, Takeshi
    ANTI-CANCER DRUGS, 2023, 34 (04) : 605 - 608
  • [38] Durable Response to Venetoclax Monotherapy in Richter's Syndrome: A Case Report and Review of Literature
    Kollipara, Revathi
    Szymanski, Kelly
    Mahon, Brett
    Venugopal, Parameswaran
    JOURNAL OF HEMATOLOGY, 2019, 8 (02) : 60 - 63
  • [39] CHRONIC LYMPHATIC LEUKEMIA BY AFFECTING THE CENTRAL NERVOUS SYSTEM WITH TRANSFORMATION TO RICHTER SYNDROME. CONTRIBUTION OF THE IMMUNOPHENOTYPIC STUDY OF THE CEREBROSPINAL FLUID AND RESPONSE TO IBRUTINIB
    Eugenia, Abella
    Lourdes, Martin-Martin
    Alberto, Orfao
    Xavier, Calvo
    Santiago, Medrano
    Eva, Gimeno
    Mariana, Ferraro
    Anna, Puiggros
    Blanca, Espinet
    Blanca, Sanchez-Gonzalez
    Antonio, Salar
    Ben Lashen Randa, Ben Azaiz
    Laia, Martinez-Serra
    Elena, Torres
    Carles, Besses
    HAEMATOLOGICA, 2016, 101 : 192 - 192
  • [40] Objective response after immune checkpoint inhibitors in a chemotherapy-refractory pMMR/MSS metastatic rectal cancer patient primed with experimental AlloStim® immunotherapy
    Ariel Hirschfeld
    Daniel Gurell
    Michael Har-Noy
    Translational Medicine Communications, 9 (1)
12345